These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
596 related articles for article (PubMed ID: 31600397)
1. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. Liu JF; Herold C; Gray KP; Penson RT; Horowitz N; Konstantinopoulos PA; Castro CM; Hill SJ; Curtis J; Luo W; Matulonis UA; Cannistra SA; Dizon DS JAMA Oncol; 2019 Dec; 5(12):1731-1738. PubMed ID: 31600397 [TBL] [Abstract][Full Text] [Related]
2. Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. Zamarin D; Burger RA; Sill MW; Powell DJ; Lankes HA; Feldman MD; Zivanovic O; Gunderson C; Ko E; Mathews C; Sharma S; Hagemann AR; Khleif S; Aghajanian C J Clin Oncol; 2020 Jun; 38(16):1814-1823. PubMed ID: 32275468 [TBL] [Abstract][Full Text] [Related]
3. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Monk BJ; Coleman RL; Fujiwara K; Wilson MK; Oza AM; Oaknin A; O'Malley DM; Lorusso D; Westin SN; Safra T; Herzog TJ; Marmé F; N Eskander R; Lin KK; Shih D; Goble S; Grechko N; Hume S; Maloney L; McNeish IA; Kristeleit RS Int J Gynecol Cancer; 2021 Dec; 31(12):1589-1594. PubMed ID: 34593565 [TBL] [Abstract][Full Text] [Related]
4. Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial. Peng Z; Li H; Gao Y; Sun L; Jiang J; Xia B; Huang Y; Zhang Y; Xia Y; Zhang Y; Shen Y; Huang B; Nie J; Chen X; Liu X; Feng C; Li Z; Zhang W; Tao K; Zhang Q; Duan S; Chen Y; Chen Y; Wang W; Zheng H; Lu Y; Liu Y; Wang L; Qi W; He Y; Tian Y; ; Li G; Ma D; Gao Q Lancet Oncol; 2024 Oct; 25(10):1288-1297. PubMed ID: 39276785 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer. Inoue Y; Yoshimura K; Nishimoto K; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Asada K; Uto T; Fujii M; Matsui T; Matsuura S; Hashimoto D; Toyoshima M; Kusagaya H; Matsuda H; Inami N; Kaida Y; Niwa M; Ito Y; Sugimura H; Suda T JAMA Netw Open; 2020 Sep; 3(9):e2011818. PubMed ID: 32955570 [TBL] [Abstract][Full Text] [Related]
6. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU; Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. Zsiros E; Lynam S; Attwood KM; Wang C; Chilakapati S; Gomez EC; Liu S; Akers S; Lele S; Frederick PJ; Odunsi K JAMA Oncol; 2021 Jan; 7(1):78-85. PubMed ID: 33211063 [TBL] [Abstract][Full Text] [Related]
16. Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer. Normann MC; Türzer M; Diep LM; Oldenburg J; Gajdzik B; Solheim O; Rud E J Gynecol Oncol; 2019 Jul; 30(4):e56. PubMed ID: 31074244 [TBL] [Abstract][Full Text] [Related]
17. Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study. Xia L; Peng J; Lou G; Pan M; Zhou Q; Hu W; Shi H; Wang L; Gao Y; Zhu J; Zhang Y; Sun R; Zhou X; Wang Q; Wu X J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017154 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer. Taylor SE; Chu T; Elvin JA; Edwards RP; Zorn KK Gynecol Oncol; 2020 Jan; 156(1):32-37. PubMed ID: 31739991 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]